Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Cyclically Adjusted Revenue per Share: ¥3.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600645 Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
65 GF Score
Price ¥19.89
GF Value ¥18.47
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted Revenue per Share?

Zhongyuan Union Cell & Gene Engineering SHSE:600645 -0.30% 65 Cyclically Adjusted Revenue per Share is ¥3.25 as of Mar. 2026. GuruFocus rates SHSE:600645 with a GF Score™ of 65/100 and a GF Value™ of ¥18.47 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhongyuan Union Cell & Gene Engineering's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.654. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥3.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zhongyuan Union Cell & Gene Engineering's average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zhongyuan Union Cell & Gene Engineering was 14.60% per year. The lowest was 1.70% per year. And the median was 9.00% per year.

As of today (2026-08-11), Zhongyuan Union Cell & Gene Engineering's current stock price is ¥19.89. Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥3.25. Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted PS Ratio of today is 6.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhongyuan Union Cell & Gene Engineering was 27.58. The lowest was 5.03. And the median was 8.97.


Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.89/3.25
=6.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhongyuan Union Cell & Gene Engineering was 27.58. The lowest was 5.03. And the median was 8.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted Revenue per Share Related Terms


Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted Revenue per Share Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.43 2.71 2.91 3.10 3.24

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 3.17 3.21 3.24 3.25

SHSE:600645 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted PS Ratio falls into.


SHSE:600645
65GF Score
Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhongyuan Union Cell & Gene Engineering Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhongyuan Union Cell & Gene Engineering's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.654/116.3033*116.3033
=0.654

Current CPI (Mar. 2026) = 116.3033.

Zhongyuan Union Cell & Gene Engineering Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.390 101.400 0.447
201609 0.565 102.400 0.642
201612 0.735 102.600 0.833
201703 0.528 103.200 0.595
201706 0.449 103.100 0.507
201709 0.819 104.100 0.915
201712 1.045 104.500 1.163
201803 0.843 105.300 0.931
201806 0.832 104.900 0.922
201809 0.843 106.600 0.920
201812 0.906 106.500 0.989
201903 0.729 107.700 0.787
201906 0.752 107.700 0.812
201909 0.777 109.800 0.823
201912 0.809 111.200 0.846
202003 0.453 112.300 0.469
202006 0.716 110.400 0.754
202009 0.743 111.700 0.774
202012 0.771 111.500 0.804
202103 0.805 112.662 0.831
202106 0.860 111.769 0.895
202109 0.827 112.215 0.857
202112 0.772 113.108 0.794
202203 0.880 114.335 0.895
202206 0.783 114.558 0.795
202209 0.806 115.339 0.813
202212 0.839 115.116 0.848
202303 0.809 115.116 0.817
202306 0.931 114.558 0.945
202309 0.807 115.339 0.814
202312 0.898 114.781 0.910
202403 0.892 115.227 0.900
202406 0.808 114.781 0.819
202409 0.929 115.785 0.933
202412 0.856 114.893 0.867
202503 0.751 115.116 0.759
202506 0.867 114.907 0.878
202509 0.817 115.471 0.823
202512 0.767 115.832 0.770
202603 0.654 116.303 0.654

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥3.25 mean?
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Cyclically Adjusted Revenue per Share of ¥3.25 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors.
Is Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted Revenue per Share too high?
Zhongyuan Union Cell & Gene Engineering's current Cyclically Adjusted Revenue per Share is ¥3.25. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Zhongyuan Union Cell & Gene Engineering's Cyclically Adjusted Revenue per Share of ¥3.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. Zhongyuan Union Cell & Gene Engineering's current Cyclically Adjusted Revenue per Share is ¥3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.47, compared to a current price of ¥19.89 — trading 7.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥3.25. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Cyclically Adjusted Revenue per Share is ¥3.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?

Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be overvalued. The current stock price of ¥19.89 is trading 7.7% above its estimated GF Value™ of ¥18.47. GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Fairly Valued.

Key valuation signals for SHSE:600645:

  • Cyclically Adjusted Revenue per Share: ¥3.25
  • GF Value™: ¥18.47 vs. price of ¥19.89 (7.7% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhongyuan Union Cell & Gene Engineering Business Description

Address 45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
65GF Score

Get the complete analysis for SHSE:600645

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.89
Price
¥18.47
GF Value